CN107011393A - A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine - Google Patents
A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine Download PDFInfo
- Publication number
- CN107011393A CN107011393A CN201610172045.6A CN201610172045A CN107011393A CN 107011393 A CN107011393 A CN 107011393A CN 201610172045 A CN201610172045 A CN 201610172045A CN 107011393 A CN107011393 A CN 107011393A
- Authority
- CN
- China
- Prior art keywords
- arginine
- glucosides
- synthesized according
- group
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004475 Arginine Substances 0.000 title claims abstract description 36
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 27
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 38
- 241000699670 Mus sp. Species 0.000 claims abstract description 32
- -1 hydroxyl radical free radical Chemical class 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 230000036039 immunity Effects 0.000 claims abstract description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims abstract description 7
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 5
- 230000004614 tumor growth Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 40
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 27
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 27
- 239000001630 malic acid Substances 0.000 claims description 27
- 235000011090 malic acid Nutrition 0.000 claims description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000008569 process Effects 0.000 claims description 16
- 229930182478 glucoside Natural products 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000011973 solid acid Substances 0.000 claims description 2
- 150000008131 glucosides Chemical class 0.000 claims 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 claims 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 40
- 238000010189 synthetic method Methods 0.000 abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 5
- 229930003268 Vitamin C Natural products 0.000 abstract description 5
- 239000011718 vitamin C Substances 0.000 abstract description 5
- 235000019154 vitamin C Nutrition 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 150000007524 organic acids Chemical class 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 239000007788 liquid Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- 235000009697 arginine Nutrition 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 29
- 102100040247 Tumor necrosis factor Human genes 0.000 description 27
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 26
- 238000012360 testing method Methods 0.000 description 24
- 108010002350 Interleukin-2 Proteins 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 22
- 102000000588 Interleukin-2 Human genes 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- 230000035484 reaction time Effects 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000001541 thymus gland Anatomy 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 229940109239 creatinine Drugs 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000009795 derivation Methods 0.000 description 7
- 230000002000 scavenging effect Effects 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229940079877 pyrogallol Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- UEZWWYVAHKTISC-JZKKDOLYSA-N NC(=N)NCCC[C@@H](C(O)=O)NCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO UEZWWYVAHKTISC-JZKKDOLYSA-N 0.000 description 4
- DLFIWFDONDYZKI-LDDAIVOZSA-N arginyl-fructose Natural products NC(N)=NCCC[C@H](NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O)C(O)=O DLFIWFDONDYZKI-LDDAIVOZSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 210000000955 splenic vein Anatomy 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical class O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229930182479 fructoside Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- YFVKHKCZBSGZPE-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one Chemical compound CCCNC(C)C(=O)C1=CC=C2OCOC2=C1 YFVKHKCZBSGZPE-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 108010065394 aminopherase Proteins 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003005 anti-senility effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- HEILIGJNYTWOHU-UHFFFAOYSA-N ethanol 2-hydroxybenzoic acid Chemical compound CCO.OC(=O)C1=CC=CC=C1O HEILIGJNYTWOHU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007540 photo-reduction reaction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of arginine monoglycosides (AF) artificial synthesis, and this synthetic method synthetic ratio is high, environmentally friendly, while suitable for industrialized production.That is the combination of arginine and one or two kinds of above monose is reacted in one or two kinds of above solvent, this reaction system can add following material, one or more kinds of mixtures in vitamin C, sodium sulfite, edible organic acid, heat time is 120 DEG C of 200min, optimal reaction temperature is 80 DEG C, the double monoglycosides of generation arginine.It can be good at removing hydroxyl radical free radical and superoxide anion present invention is disclosed the arginine monoglycosides after synthesis, while H can be suppressed22The growth of tumor-bearing mice tumour, improves the immunity of immunosuppressed mice.
Description
Technical field
The present invention relates to a kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medical treatment.
Background technology
Arginine monoglycosides English entitled Arginyl-Fructose, abbreviation AF, also known as arginine fructoside, molecular weight
For 337.3, chemical name is 1-(Arginine-NαBase)- 1- deoxidation-D fructose.AF monomers after purification are white powder, AF poles
It is soluble in water, the organic solvents such as methanol are practically insoluble in, with hygroscopicity, to thermally labile.
Arginine monoglycosides(AF), be present in many plants of nature, Zheng Yinan it is fresh ginseng be processed into red ginseng, it is sun-dried
During ginseng, it was found that AF presence.Contents of the AF in nature is very low, but research is found in processing of Panax ginseng into sun-dried
AF contents are higher when ginseng, red ginseng.After AF is the heated working process of fresh ginseng, it is anti-that Mei Lade occurs for sugar and amino acid in ginseng
It should generate[1,2].Research finds that AF has very strong pharmacological activity, positive role is played in disease treatment.Grind at present
Study carefully and show, AF is in anti-diabetic[3,4], it is anti-oxidant[5,6], it is antitumor[7], play a role in the treatment such as liver protection.
The method of current arginine monoglycosides synthesis is mainly patent " arginine fructoside (AF) preparation method and its medical
Purposes, application number:201410305612.1 " are reported, but its method solvent selected in building-up process is not only dirty
Environment is contaminated, is hazardous to the human body, synthetic ratio is relatively low, process is also complex for follow-up isolating and purifying, and the present invention is on overcoming
State and a kind of new synthesis technique is developed in synthesis defect, and disclose some biological activity of arginine glucoside after synthesis.
The content of the invention
The purpose of the present invention is the synthetic method and its medical application for disclosing a kind of arginine monoglycosides.
The synthetic method synthetic ratio of arginine monoglycosides disclosed by the invention is more than 63%, and the proportioning of arginine and monose is
1:0.5-2.
Arginine required in the synthetic method of arginine monoglycosides disclosed by the invention can be L-arginine, D- essences
The mixture of propylhomoserin one or two kinds of therein.
Monose required in the synthetic method of arginine monoglycosides disclosed by the invention can be D-Glucose, D- fruits
One or more kinds of mixtures in sugar, D- galactolipins, D- xyloses.
Generated time required in the synthetic method of arginine monoglycosides disclosed by the invention is 120-300min.
Synthesis temperature required in the synthetic method of arginine monoglycosides disclosed by the invention is 80 DEG C.
In the synthetic method of arginine monoglycosides disclosed by the invention required for solvent for propane diols, glycerine, propyl alcohol,
One or more kinds of mixed solvents in isopropanol.
Sodium sulfite, vitamin C, vitamin can also be added in the synthetic method of arginine monoglycosides disclosed by the invention
One or more kinds of mixtures in E.
It is edible that citric acid, malic acid etc. can also be added in the synthetic method of arginine monoglycosides disclosed by the invention
One or more kinds of mixtures in organic solid acid.
The arginine monoglycosides of synthesis disclosed by the invention, which have, to be removed hydroxyl radical free radical and ultra-oxygen anion free radical, resists
Tumour, the purposes for improving immunity.
The positive effect of the present invention is:AF synthetic method in the present invention, synthetic ratio is greatly improved, and reachable 63%, together
When reduce AF production cost, and thick synthetic has no irritating odor, and belongs to the synthetic method of green environment friendly.
Experiments show that, the AF of synthesis has removing free radical, work(that is antitumor and improving immunity of organisms
Effect.
The arginine monoglycosides of experimental example 1.(AF)Synthesis technique
1.1 experimental method
1.1.1 the drafting of standard curve
Precision weighs the mg of AF reference substances 5, with water constant volume in 25 mL volumetric flasks, 2,4,6,8 mL reference substances is pipetted respectively molten
Liquid is settled to scale in 10 mL volumetric flasks with water, obtains the control that mass concentration is respectively 0.1,0.2,0.3,0.4 mg/mL
Product solution.
HPLC conditions:Venusil-AA amino acid analysises dedicated columns (5 μm, the mm of 4.6 mm × 250);Mobile phase:A phases-
Sodium acetate buffer solution(925 mL pure water, 7.6 g sodium acetates, 2 mL phosphoric acid, 2-3 d glacial acetic acids, 75 mL acetonitriles), B phases-
Organic phase(Acetonitrile: water=4: 1).The mL/min of flow velocity 1.0;The nm of Detection wavelength 254;40 DEG C of column temperature;The μ L of sample size 20.
1.1.2 single factor experiment
1.1.2.1 optimum reacting time is screened
Fixed 85 DEG C of reaction temperature, solid-liquid ratio 1:20, the g of malic acid addition 0.75, investigate the reaction time be 60,90,120,
150th, influences of 180 min to AF synthetic ratios.
1.1.2.2 optimal reaction temperature is screened
The min of fixation response time 150, solid-liquid ratio 1:20, the g of malic acid addition 0.75, investigate reaction temperature be 70,75,80,
85th, 90 DEG C of influences to AF synthetic ratios.
1.1.2.3 screen optimal solid-liquid ratio
The min of fixation response time 150,85 DEG C of reaction temperature, the g of malic acid addition 0.75 investigates solid-liquid ratio 1:10、1:15、
1:20、1:25、1:Influences of 30 g/mL to AF synthetic ratios.
1.2.2.4 optimal malic acid addition is screened
The min of fixation response time 150,85 DEG C of reaction temperature, solid-liquid ratio 1:20, malic acid addition 0.5,0.75,1.0 is investigated,
Influences of 1.25 g to AF synthetic ratios.
1.1.3 response phase method is tested
On the basis of single factor test, using statistical analysis software DesignExpert 8.0.6, according to Box-Behnken center
Combination experiment design principle, with the reaction time(X1), reaction temperature(X2), solid-liquid ratio(X3), malic acid addition(X4)To become certainly
Amount, AF synthetic ratios(Y)For response, optimize, experimental factor is as shown in table 1 with level code.
The response surface optimization experimental factor level of table 1
1.2 result of the test
1.2.1 the drafting of standard curve
Peak area of the AF reference substance solutions of various concentrations under 254 nm is determined, with mass concentration X (mg/mL) to peak area
Y draws standard curve, and obtaining regression equation is:Y=298449.88X, R2=0.9991, in the mg/ of mass concentration 0.1 ~ 0.5
It is in good linear relation in mL.
1.2.2 single factor experiment
1.2.2.1 influence of the reaction time to AF synthetic ratios
In the case where other experimental conditions are constant, with the extension of time, the acid catalyzed AF synthetic ratios of apple gradually rise,
When the time reaching 150 min, synthetic ratio peaks, as reaction continues, and reacts to AF and reduces direction progress.Therefore,
The scope in the reaction time that Box-Behnken experiments are chosen is 120-180 min(Accompanying drawing 1).
1.2.2.2 influence of the reaction temperature to AF synthetic ratios
Test of many times finds that when between 70-90 DEG C of temperature, AF synthetic reaction occurs rapidly, meets what AF was formed in red ginseng
Temperature conditionss, when temperature reaches 85 DEG C, AF synthetic ratios peak, as temperature continues to raise, synthetic ratio reduction.Cause
This, the scope for the reaction temperature that Box-Behnken experiments are chosen is 80-90 DEG C(Accompanying drawing 2).
1.2.2.3 influence of the solid-liquid ratio to AF synthetic ratios
In the case where other experimental conditions are constant, during using solid-liquid ratio as variable, when glycerine dosage is too low, reaction is difficult to mix
It is even, and react not thorough, synthetic ratio is relatively low, with the increase of solvent volume, reaches 1:During 20 g/mL, AF synthetic ratio highests, with
Glycerine volume to continue to increase, synthetic ratio declines.Therefore, the scope for the solid-liquid ratio that Box-Behnken experiments are chosen is 1:15-
1:25 g/mL(Accompanying drawing 3).
1.2.2.4 influence of the malic acid addition to AF synthetic ratios
In the case where other experimental conditions are constant, with the increase of malic acid addition, AF synthetic ratio gradually rises, apple
When sour addition reaches 0.75g, synthetic ratio reaches maximum, is then decreased with the increase of malic acid content.Therefore,
The scope for the malic acid addition that Box-Behnken experiments are chosen is 0.5-1.0 g(Accompanying drawing 4).
1.2.3 response phase method optimum synthesis test results and analysis
1.2.3.1 result of the test
Box-Behnken designs are carried out with the analysis softwares of Design Expert 8.0, design and its result of the test are shown in
Table 2,1-24 factorial experiments of tested number, 25-29 multi-center trials of tested number.
1.2.3.2 interpretation of result
Result of the test to table 2 is analyzed, and obtains AF synthetic ratios(Y)To reaction temperature(X1), the reaction time(X2), solid-liquid ratio
(X3), acid adding amount(X4)Secondary multinomial regression equation be:
Y=67.79+2.96X1+1.74X2-1.77X3+1.05X4+1.24X1X2+1.53X1X3+1.72X2X3-1.55X2X4-
2.01X3X4-5.15X1 2-6.09X2 2-5.49X3 2-6.62X4 2。
Table 3 is the results of analysis of variance of regression model, and model F values are 53.18, R2=0.9815, P<0.0001, explanation
You and degree of regression equation are preferable, and experiment is with very high credibility and accuracy.The amendment coefficient R of model2Adj=
0.9631, show that the equation preferably reflects generated time, synthesis temperature, solid-liquid ratio and malic acid addition and AF synthetic ratios
Relation, illustrate that the model can explain 96.31% response value changes, therefore available synthesis of this model to AF is analyzed
And prediction.From the analysis result of F values(A=95.2、B=32.83、C=34.03、D=11.89)As can be seen that in selected each factor
In horizontal extent, the order of the influence size to AF synthetic ratios is:Reaction temperature > solid-liquid ratio > reaction time > malic acid adds
Enter amount.
The Box-Behnken experimental designs scheme of table 2 and result
The regression model the results of analysis of variance of table 3
R2=0.9815, R2Adj=0.9631, R2Pred=0.9159, CV=1.81
1.2.3.3 the response surface analysis of AF synthesis techniques and optimization
Accompanying drawing 6,10 curved surfaces are precipitous, and contour is oval, illustrate reaction temperature and solid-liquid ratio, solid-liquid ratio and malic acid addition
There is very strong reciprocation, in pole conspicuousness;The curved surface of accompanying drawing 5,6,8 is relatively gentle, illustrates reaction temperature and reaction time, reaction
Temperature has certain reciprocation with solid-liquid ratio, reaction time and solid-liquid ratio, but contour is almost circular, and reciprocation is not
It is very strong;The curve of accompanying drawing 7, contour is circle, illustrates that reaction temperature and malic acid addition reciprocation be not notable.Accompanying drawing
There is extreme value in 9, illustrate that the selected scope of experiment is more reasonable.
1.2.3.4 the determination of AF synthetic technological conditions
Understood with reference to analysis of regression model result, the optimum process condition of AF synthesis is 85 DEG C of reaction temperature, reaction time 150
Min, liquid ratio 1:20(g/mL), the g of malic acid addition 0.75.AF theoretical synthetic ratio is 67.79% on this condition, actual
Synthetic ratio is 68.92%, and theoretical value is coincide substantially with actual value.As can be seen here, the optimal synthesis work that Responds Surface Methodology is optimized
Skill data are true and reliable.
1.3 discuss
AF synthesis techniques are optimized using Response Surface Method, by rational experimental design, so as to draw each factor to AF synthetic ratios
Influence size is followed successively by:Reaction temperature>Solid-liquid ratio>Reaction time>Malic acid addition.Solid-liquid ratio and malic acid addition are to AF
The reciprocal effect of synthesis is the most notable.Its optimum synthesis condition is 85 DEG C of reaction temperature, the min of reaction time 150, solid-liquid ratio 1:
20(g/mL), malic acid addition 0.75 g, AF actual synthetic ratio be 68.92%.Test the Responsive surface model used notable
Property is preferable so that accurately and reliably, the result of study is to the further perfect of artificial synthesized AF methods, with certain reason to result
By reference value and actual application prospect.
AF monomers content in nature is low, isolates and purifies difficulty, therefore uses artificial synthesized method, to reduce AF synthesis
Cost, improves value.Zhao Ting, Zheng Yinan etc. using glacial acetic acid as catalyst AF synthetic ratio are 20-30% or so.Glacial acetic acid
It is a kind of organic acid, and has strong impulse smell, its steam is to eye and the irritant effect of nose.Herein with malic acid
It is general AF preferably one of the selections of synthesis food medicine for catalyst.The use of malic acid, solves glacial acetic acid penetrating odor
Shortcoming, and optimize AF synthesis techniques using response phase method, it preferably handles discrete levels value, experimental period is short, precision
Height, can study factor interaction, filter out optimum synthesis condition, significantly improve AF synthetic ratios, be next step
Research lays the foundation, and also makes it possible a large amount of production and applications of AF.
The arginine monoglycosides of experimental example 2(AF)Scavenging action to hydroxyl radical free radical and ultra-oxygen anion free radical
The preparation of 2.1 AF sample solutions
L-arginine 10g, glucose 10g, the g of malic acid 15 are taken, is dissolved in 200 mL glycerine, shakes up, in 85 DEG C of water-bath bars
90 min are reacted under part, the total synthetics of AF are obtained, high-effective cationic post is splined on, 1.5 % ammoniacal liquor elution, part receiver connects sample,
After batch processing, sample measures purity by HPLC, and vacuum freeze drier is freezed as white powder.Cation seperation column is repeatedly pure
Change, its purity is surveyed through efficient liquid phase, more than 95%.AF after purification is taken, the sample that mass concentration is 1 mg/mL is configured to water
Solution, based on this concentration, is progressively diluted to 0.5,0.4,0.1,0.08,0.05 mg/mL sample solutions, stand-by.
2.2 Antioxidative Activity Determination
2.2.1 scavenging actions of the AF to hydroxyl radical free radical
2.2.1.1 hydroxyl radical free radical generation structure
This experiment uses Fenton methods, sets up OH radical reaction system models.Its reactional equation is:H2O2+ Fe2+ →
OH-+ OH+Fe3+, the time of OH survivals is short, but has very high reactivity.And salicylic acid can effectively be caught
OH, produces the complex compound of certain color, and the color product has strong absorption at 500 nm.If in this experiment, AF has clear
Except OH functions, then OH is fought for salicylic acid, so that colored complex growing amount is reduced, color mitigates.So, utilize this
Method, is contrasted with blank control pipe, so that it may the removing OH free radical effects of determination sample.Clearance rate calculation formula is:
E(·OH)/ %=1-(A i-A j )×100%
A
o
EFor the clearance rate of hydroxyl radical free radical;A oFor blank control pipe absorbance;A iFor reaction solution absorbance;A jNot add salicylic acid
The absorbance of extract solution itself.
2.2.1.2 the preparation of solution
FeSO4Solution(6 mmol/L):Weigh FeSO4The g of crystal 0.0456, with water constant volume in 50 mL volumetric flasks, is configured to 6
Mmol/L solution, it is stand-by.
H2O2(30%):Take 30% H2O213.6 μ L constant volumes are configured to 2.4 mmol/L solution, treated in 50 mL volumetric flasks
With.
Salicylic acid-ethanol solution(6 mmol/L):The g of salicylic acid solid 0.0414 is weighed, with absolute ethyl alcohol constant volume in tin
In the 50 mL volumetric flasks that paper bag is wrapped up in, 6 mmol/L solution are configured to, it is stand-by.
2.2.1.3 the measure of hydroxyl radical free radical
A oThe measure of value:2 mL water are added in test tube, 6 mmol/LFeSO are added4Solution 2 mL, 2.4 mmol/LH2O2It is molten
The mL of liquid 2, shakes up, at room temperature static 10 min, afterwards, adds 6 mmol/L salicylic acids-mL of ethanol solution 2,37 DEG C of water-baths 30
Min, centrifugation(3000 r/min,10 min), abandoning supernatant, 500 nm determine its absorbance.
A iThe measure of value:The mL of 0.5,0.4,0.1,0.08,0.05 mg/mL AF solution 2 is separately added into test tube, then
Add 6 mmol/LFeSO4Solution 2 mL, 2.4 mmol/LH2O2The mL of solution 2, shakes up, at room temperature static 10 min, afterwards, plus
Enter 6 mmol/L salicylic acids-ethanol solution 2 mL, 37 DEG C of min of water-bath 30, centrifuge(3000 r/min,10 min), discard
Clear liquid, 500 nm determine its absorbance.
A jThe measure of value:The mL of 0.5,0.4,0.1,0.08,0.05 mg/mL AF solution 2 is separately added into test tube, then
Add 6 mmol/LFeSO4Solution 2 mL, 2.4 mmol/LH2O2The mL of solution 2, shakes up, at room temperature static 10 min, afterwards, and 37
DEG C min of water-bath 30, centrifugation(3000 r/min,10 min), abandoning supernatant, 500 nm determine its absorbance.
2.2.2 scavenging actions of the AF to ultra-oxygen anion free radical
2.2.2.1 ultra-oxygen anion free radical generation structure
This experiment determines AF to O using assay NBT photoreduction2 -The Scavenging activity of free radical.Pyrogallol is in alkalescence condition
Lower autoxidation, generation ultra-oxygen anion free radical O2 -With autoxidation intermediate product, the product has absworption peak at 420 nm, its
Oxidation process is:The first step, mouse thymus cells are into Semiquinone Radicals;Second step, is oxidized to quinone, adjoint in the process
The generation of superoxide radical.
If AF oxidation resistances are stronger, mouse thymus cells process will be hindered, O2 -The generation of free radical is just
It can be suppressed, absworption peak weakens, determination sample is come with absorbance and removes O2 -The ability of free radical.Clearance rate calculation formula
It is as follows:
E(O2 -)/ %=1-(A i-A j )×100%
A
o
E For the clearance rate of ultra-oxygen anion free radical;A oFor blank control pipe absorbance;A iFor reaction solution absorbance;A jFor not
Plus the absorbance of pyrogallol itself.
2.2.2.2 the preparation of solution
Pyrogallol solution(25 mmol/L):The g of pyrogallol crystal 0.158 is weighed, with water constant volume in 50 mL volumetric flasks,
25 mmol/L solution are configured to, it is stand-by.
Hydrochloric acid(80 mmol/L):Pipette draws 2 mL hydrochloric acid, and constant volume is configured to 80 in 25 mL volumetric flasks
Mmol/L hydrochloric acid solutions, it is stand-by.
Phosphate buffer(PH=8,0.05 mol/L):The g of disodium hydrogen phosphate 7.164 is weighed, with water constant volume in 100 mL
In volumetric flask, fully dissolving;The g of sodium dihydrogen phosphate 3.121 is weighed, with water constant volume in 100 mL volumetric flasks, fully dissolving;Point
Not Xi Qu the disodium hydrogen phosphate aqueous solution 22.88 mL, the mL of biphosphate sodium water solution 2.125 in 100 mL volumetric flasks, constant volume,
Fully mix, be configured to PH=8,0.05 mol/L phosphate buffers, it is stand-by.
2.2.2.3 the measure of superoxide anion
A oThe measure of value:The mL of PH=8,0.05 mol/L phosphate buffers 4.5 is added in test tube, is added in 25 DEG C of water-baths
20 min of heat, afterwards, add 1 mL water and 25 mmol/L pyrogallol solution, after mixing, 25 DEG C of 10 min of reaction, add 80
The mL terminating reactions of mmol/L hydrochloric acid solutions 1, are shaken up, and react 3 min, and its absorbance is surveyed at 420 nm.
A iThe measure of value:The mL of PH=8,0.05 mol/L phosphate buffers 4.5 is added in test tube, in 25 DEG C of water-baths
20 min of middle heating, afterwards, are separately added into the mL of 0.5,0.4,0.1,0.08,0.05 mg/mL AF sample solutions 1 and 25
Mmol/L pyrogallol solution, after mixing, 25 DEG C of 10 min of reaction add the mL terminating reactions of 80 mmol/L hydrochloric acid solutions 1,
Shake up, react 3 min, its absorbance is surveyed at 420 nm.
A jThe measure of value:The mL of PH=8,0.05 mol/L phosphate buffers 4.5 is added in test tube, in 25 DEG C of water-baths
20 min of middle heating, afterwards, are separately added into the mL of 0.5,0.4,0.1,0.08,0.05 mg/mL AF sample solutions 1, after mixing,
25 DEG C of 10 min of reaction, add the mL terminating reactions of 80 mmol/L hydrochloric acid solutions 1, shake up, react 3 min, surveyed at 420 nm
Its absorbance.
2.3 result
2.3.1 AF is to hydroxyl radical free radical Scavenging activity
Experimental result is shown, with the increase of AF sample quality concentration, the Scavenging activity of hydroxyl radical free radical is gradually strengthened, works as AF
During 0.5 mg/mL, clearance rate reaches 78.14 %.This time result shows, AF can play removing hydroxyl radical free radical effect, and effect
Really obvious, concrete numerical value is shown in Table 4.
The AF of table 4 is to hydroxyl radical free radical Scavenging activity
AF mass concentrations(mg/mL) | Ai | Aj | Ai- Aj | E(·OH)/% |
Blank | 0.837 | 0.256 | 0.581 | — |
0.5 | 0.782 | 0.236 | 0.546 | 78.14 |
0.4 | 0.816 | 0.246 | 0.570 | 72.18 |
0.1 | 0.851 | 0.256 | 0.595 | 69.70 |
0.08 | 0.911 | 0.274 | 0.637 | 62.47 |
0.05 | 0.979 | 0.284 | 0.685 | 52.49 |
2.3.2 AF is to ultra-oxygen anion free radical Scavenging activity
Experimental result is shown, with the increase of AF sample quality concentration, the Scavenging activity of ultra-oxygen anion free radical is gradually increased
By force, as 0.5 mg/mL of AF, clearance rate reaches 78.94 %.This time result shows, AF can play removing superoxide anion certainly
Acted on by base, and effect is obvious, concrete numerical value is shown in Table 5.
The AF of table 5 is to ultra-oxygen anion free radical Scavenging activity
AF mass concentrations(mg/mL) | Ai | Aj | Ai- Aj | E(·OH)/% |
Blank | 0.314 | 0.029 | 0.285 | — |
0.5 | 0.090 | 0.030 | 0.060 | 78.94 |
0.4 | 0.119 | 0.033 | 0.086 | 69.82 |
0.1 | 0.149 | 0.030 | 0.119 | 58.24 |
0.08 | 0.174 | 0.029 | 0.145 | 49.12 |
0.05 | 0.189 | 0.031 | 0.158 | 44.56 |
2.4 brief summary
The result of this experiment shows that AF can preferably remove superoxide anion and hydroxyl radical free radical, and with the increase of AF concentration,
Scavenging activity is also in enhancing, and when AF concentration is 0.5 mg/mL, hydroxyl radical free radical clearance rate reaches 78.14%, superoxide anion
Free radical scavenging activity reaches 78.94%, shows that AF has stronger oxidation resistance, its specific mechanism also needs to further research.
The arginine monoglycosides of experimental example 3(AF)H22 tumor-bearing mices Tumor growth inhibition is acted on
3.1 test method
3.1.1 modeling method
Take H22Oncocyte liquid(Special product research institute provides), it is inoculated in after mouse peritoneal, 7-9 d, dislocated execution, 75% alcohol
Pasteurised completely, aseptically extracts mouse ascites, is placed in the test tube with ground stopper for filling physiological saline, mixes, centrifugation(1000
R/min, 3 min), abandoning supernatant, and brine is used, it is repeated 3 times, finally adjusts tumor cell suspension with physiological saline
Cell number is 1.0 × 107Individual/mL, subcutaneous vaccination is in ICR mouse right fores, and 0.2mL/ is only.
3.1.2 animal packet and administration
After the h of mouse inoculation 24, success Mice Inoculated is randomly divided into 5 groups, every group 10, i.e. model group(M, 0.9% physiology salt
Water), positive controls(P, endoxan, 25 mg/kg), AF low dose groups(AF-L,12.5 mg/kg), AF middle dose groups
(AF-M,25 mg/kg)AF high dose groups(AF-H,50 mg/kg), each group is administered by 10 mL/kg mouse weights daily, positive
Control group intraperitoneal injection, remaining each group gavage gives corresponding medicine, and (blank control group and model group give 0.9% physiology
Salt solution), it is administered once a day, the d of successive administration 21.
3.1.3 tumour inhibiting rate is determined
After the h of last dose 12, eyeball takes blood and after the execution mouse that dislocates, clamps mouse tumor area skin with tweezers on the other hand, separately
One hand that operating scissors cuts off skin, and exposure tumour, with operating scissors along tumor's profiles, is peeled off tumour, carried out with 9% physiological saline
Rinsing, filter paper is weighed after blotting, and calculates tumour inhibiting rate.
Tumour inhibiting rate(%)=(The average knurl weight of the average knurl weight-experimental group of model group)The % of the average knurl weight of ÷ model groups × 100.
3.1.4 organ index
After the h of last dose 12, eyeball takes blood, the r of centrifuge 4500 separation serum, the serum keeping after processing in -20 DEG C of refrigerators,
It is stand-by.The dissection of system is carried out after mouse is put to death, spleen and thymus gland is taken out, is rinsed with 9% physiological saline, filter paper is blotted
After weigh, calculate spleen index and thymus index.
The body weight (g) of organ index=organ weights (g) × 100/
3.1.5 biochemical indicator is detected
3.1.5.1 liver function and renal function index are determined
By determining serum Glutamic Acid aminopherase(ALT)And aspartate amino transferase(AST), urea nitrogen
(BUN) and creatinine (CRE) content, to reflect influence of the medicine to liver, renal function.
3.1.5.2 in hepatic tissue SOD vigor and MDA contents measure
SOD vigor is detected with xanthine oxidase, thiobarbituricacidα- is used(TBA)Method detects MDA contents, in strict accordance with examination
Agent box specification is operated.
3.1.5.3 TNF-α, IL-2 assays in serum
The mice serum dispensed is taken, normal temperature unfreezing is operated in strict accordance with ELISA specifications, clicks and enters 96 orifice plates, and ELIASA is determined
Afterwards, Data Management Analysis is carried out.
3.1.6 tumor tissue pathology checks
Take the tumor tissues after dissection to be fixed in 10% formaldehyde fixer, be dehydrated, transparent, waxdip, finally embedded.With cutting
Tumor tissues after embedding are cut into 4 ~ 5 μm by piece machine, are then extended piece, are dragged for piece, piece dried, by the section handled well, through H&E
After decoration method dyeing, the structure of tissues observed and the form of cell, are finally analysed and compared under the microscope.
3.1.7 statistical analysis
Analyzed using SPSS17.0 application software, data with mean+SD (± s) represent.Multigroup is compared and adopts
With one-way analysis of variance method, withP<0.05 represents that difference is statistically significant.
3.2 experimental result
3.2.1 AF is to H22The tumor-inhibiting action of tumor-bearing mice
As shown in table 6, AF-L, AF-M dosage group tumour is played must inhibitory action, compared with model group, existed extremely notable
Difference(p<0.01), but tumour inhibiting rate is less than positive controls.There was no significant difference with model group for AF-H groups.Three agent of AF administrations
Amount foot, is compared, and AF-L groups tumor killing effect is best, inhibitory rate to 47.65%.
The AF of table 6 is to H22Tumor-bearing mice tumor-inhibiting action (±s, n=10)
Groups | Dosage(mg/kg) | Tumor weight (g) | Inhibitory rate(%) |
Model | — | 1.82 | — |
Positive | 25 | 0.85** | 53.37 |
AF-L | 12.5 | 0.95** | 47.65 |
AF-M | 25 | 1.24** | 31.81 |
AF-H | 50 | 1.67 | 9.08 |
*p<0.05, ** p<0.01, vs. model group
3.2.2 AF is to H22The influence of tumor-bearing mice immune organ
As shown in table 7, the raising that AF can be different degrees of to the thymus index and renal index of mouse.With blank control group ratio
Compared with model group has significant difference with positive controls(p<0.01), there is significant difference in AF-H group thymus indexs(p<
0.05).Compared with model group, AF-L, AF-M, AF-H dosage group have pole significant difference(p<0.01).
The AF of table 7 is to H22Tumor-bearing mice immune organ influence (±s, n=10)
Group | Dosage(mg/kg) | Spleen index(mg/g) | Thymus index(mg/g) |
Normal | — | 0.57±0.04** | 0.23±0.01** |
Model | — | 0.39±0.02## | 0.16±0.02## |
Positive | 25 | 0.47±0.05**## | 0.19±0.02*## |
AF-L | 12.5 | 0.530±0.02** | 0.21±0.03** |
AF-M | 25 | 0.55±0.03** | 0.22±0.02** |
AF-H | 50 | 0.54±0.05** | 0.20±0.01** |
*p<0.05, ** p<0. 01, vs. model group; #p<0. 05, ## p<0. 01, vs. normal control group
3.2.3AF to H22The influence of tumor-bearing mice cell factor
As shown in table 8, with blank control group there is pole significant difference in model group.Compared with model group, positive controls, AF-
L, AF-M group Serum IL-2 significantly rise, and there is pole significant difference(p<0.01);There is significant difference in AF-H groups
(p<0.05).Compared with M groups, P, AF-L, AF-M, AF-H group TNF-α content are significantly improved, pole conspicuousness is presented(p<
0.01).
The AF of table 8 to cytokine TNF-α in mice serum, IL-2 influence (±s, n=10)
Groups | Dosage(mg/kg) | IL-2 (pg/mL) | TNF-α(pg/mL) |
Normal | — | 71.08±10.76 | 148.21±28.03 |
Model | — | 39.27±5.95## | 110.39±16.45## |
Positive | 25 | 65.56±7.23** | 174.05±41.35** |
AF-L | 12.5 | 56.53±6.68** | 161.29±21.55** |
AF-M | 25 | 80.17±5.64** | 145.82±25.35** |
AF-H | 50 | 51.21±7.28* | 144.61±16.26** |
*p<0.05, ** p<0.01, vs. model group;#p<0.05, ## p<0.01, vs. normal control group
3.2.4 AF is to H22The influence of tumor-bearing mice hepatic and renal function
Compared with blank control group, model group CRE, BUN content has pole significant difference(p<0.01).With model group ratio
Compared with positive controls CRE contents have significant difference(p<0.05);There is pole significant difference in AF-L, AF-M group CRE contents
(p<0.01);AF-H groups are with model group without significant difference.BUN contents in serum, compared with model group, positive controls, AF-L
Pole significant difference is presented in group(p<0.01);There is significant difference in AF-M, AF-H group(p<0.05).
Each dosage groups of AF can significantly reduce serum alt, AST contents.Model group exists extremely notable with blank control group
Sex differernce(p<0.01);Compared with model group, positive controls, AF-L, AF-M, AF-H group serum alt content have pole
Significant difference;In positive controls, AF-L, AF-H group serum there is pole significant difference in AST contents(p<0.01), AF-M groups
There is significant difference(p<0.05), as shown in table 9.
The AF of table 9 is to H22Tumor-bearing mice hepatic and renal function influence (±s, n=10)
*p<0.05, ** p<0.01, vs. model group; #p<0. 05, ## p<0. 01, vs. normal control group
3.2.5 AF is to H22The influence of tumor-bearing mice SOD and MDA content
As shown in table 10, with blank control group there is pole significant difference in model group.Compared with model group, administration group mouse liver
SOD contents are significantly increased in tissue, and positive controls, AF-L, AF-M, AF-H group have significant difference(p<0.01).
Compared with model group, MDA contents are significantly raised in positive controls, AF-L, AF-M liver organization(p<0.01), AF-H groups and mould
Type group no significant difference.
The AF of table 10 is to H22Tumor-bearing mice SOD and MDA content influence (±s, n=10)
Groups | Dosag(mg/kg) | SOD(U/mgprot) | MDA(nmol/mgprot) |
Normal | — | 216.95±17.57 | 10.06±2.08 |
Model | — | 124.78±15.06## | 14.88±0.92## |
Positive | 25 | 210.98±15.64** | 10.79±2.06** |
AF-L | 12.5 | 251.26±30.88** | 8.17±2.24** |
AF-M | 25 | 166.70±29.47** | 8.79±2.43** |
AF-H | 50 | 163.24±34.17** | 13.70±1.85 |
*p<0.05, ** p<0. 01, vs. model group; #p<0.05, ## p<0.01, vs. normal control group
3.3 brief summaries are with discussing
H22Tumor cell line, rate of vaccination is higher, and tumour is complete after being inoculated with successfully, and is not susceptible to transfer, convenient to tumour growth
Observation directly perceived, the measurement of gross tumor volume and weight the features such as.At present, in domestic and international Tumor Assays research, mostly with H22Tumour
Cell line is model.This experiment is with H22Tumor-bearing mice is test model, studies AF antitumor activities, as a result shows, AF-L groups are made
With obvious, inhibitory rate to 47.65%, less than endoxan positive controls inhibiting rate(53.37%), but both are not present
Significant difference.
The generation of tumour is contacted with immune system there is also larger, and the two complements each other.Development, transfer, the leaching of tumour
Profit, deterioration etc. are all along with the decline of immunologic function[8].So during oncotherapy, how to improve the anti-of body itself
Anti-tumor immunity, which is caused, widely to be probed into[9-10].Two important immune organs of body, thymus gland and spleen, its internal organs refer to
Number is often used in the immunocompetent height of evaluation[11].This paper results show, AF-L, AF-M, AF-H group thymus index and spleen
Index is significantly higher than model control group, and there is significant difference(p<0.01), thus illustrate, AF can delay tumor-bearing mice to exempt from
Epidemic disease organ failure.IL-2, TNF-α play vital effect in anti-tumor-bearing mice is immune.IL-2 is that T cell growth must
The growth factor of palpus, while the immunologic function of B cell, NK cells, macrophage etc. can be raised, can also stimulate TNF, interference
The secretion of the others cell factor such as element[12].TNF-α be the activity most strong antitumor cell that finds both at home and abroad at present because
Son[13], it is produced by the mononuclear macrophage activated, can directly dissolve tumour, can also be resisted microorganism invasion and be adjusted
The function of immunity of organism.This experimental study shows that AF-L, AF-M group can improve IL-2 in mice serum, TNF-α content, with
Be present pole significant difference in model group, you can illustrate, AF-L, AF-M group can strengthen the body's immunity of tumor-bearing mice, from
And suppress the growth of tumour.
Glutamic-pyruvic transaminase(ALT)And glutamic-oxalacetic transaminease(AST)In main enrichment liver organization, so liver organization is damaged
Wound or during severe necrosis, ALT and AST are largely leaked into serum, therefore the two content is significantly raised in serum, so, often with
Whether serum alt, AST contents height damage or downright bad important indicator to monitor liver.In this experiment, in administration group serum
ALT, AST content are below model group, and there is significant difference, with blank control group without significant change, illustrate AF to mouse
Liver not damaged.BUN, CRE are one of clinically conventional leading indicators of detection renal function.When glomerular filtration rate(GFR declines
During to normal less than 50%, BUN concentration is raised rapidly.When with diseases such as acute and chronic glomerulonephritis, filter glomerulus
Cross hypofunction, CRE rises.This time test, BUN, CRE content are substantially less than model group in serum(p<0.01), with blank
There was no significant difference for control group, illustrates AF to tumor-bearing mice renal function not damaged.
There is certain relation in generation, the development of free radical and tumour[14-15].SOD is a kind of antioxidase, is antioxygen
The first line of defence of change, can be disproportionated into H by super positive anion2O2, and the change of MDA contents can oxygen in response organization indirectly
The change of free-radical contents.Therefore the oxidation resistant ability of body can be reflected by determining SOD, MDA content[16].Result of the test
It has been shown that, AF can significantly improve SOD value(p<0.01), AF-L, AF-M group can significantly reduce MDA value(p<0.01), explanation
AF can improve the oxidation resistance of body, remove interior free yl.
In summary, AF have must antitumous effect, especially AF low dose groups, performance the most substantially, its energy
It is enough substantially to suppress the growth of tumour, and immunity of organism activity can be improved.But the thorough treatment of tumour, is a long process, also
Need further exploratory development.
The arginine monoglycosides of experimental example 4(AF)Influence to immunosuppressed mice immunologic function
4.1 experimental method
4.1.1 animal packet and dosage
100 ICR mouse, after adaptability is raised one week, are randomly divided into 5 groups, suppression is immunized in every group 20, i.e. Normal group (N)
Simulation group (M), immunosupress AF low dose groups(M-L, 20 mg/kg), immunosupress AF middle dose groups(M-M, 40
mg/kg), immunosupress AF high dose groups(M-H, 80 mg/kg).Each group is given by 10 mL/kg body weight to mouse stomach daily
Medicine, is administered once a day, the d of successive administration 28.M, M-L, M-M and M-H group, weekly first three day, intraperitoneal injection of cyclophosphamide
(CTX, 80 mg/kg), form immunosupress.
4.1.2 mouse immune organ organ index is determined
After the h of last dose 12, eyeball takes blood, the r of centrifuge 4500 separation serum, the serum keeping after processing in -20 DEG C of refrigerators,
It is stand-by.The dissection of system is carried out after mouse is put to death, spleen and thymus gland is taken out, is rinsed with 9% physiological saline, filter paper is blotted
After weigh, calculate spleen index and thymus index.
The body weight (g) of organ index=organ weights (g) × 100/
4.1.3 external Splenic vein hemodynamics experiment
It is administered after 21d, every group is randomly selected 10 mouse, and dislocation is put to death, puts in 75 % alcohol and soak 5 min, sterile to take spleen
It is dirty, RPMI-1640 is added, the grinding of 300 mesh steel meshes draws splenocyte suspension in 1.5 mL centrifuge tubes, centrifuges 10 min
(15000 rpm, 4 DEG C), abandon supernatant.ACK Lysis Buffer are added in above-mentioned centrifuge tube, 10 min are centrifuged again
(15000 rpm, 4 DEG C), abandon supernatant.RPMI-1640 is added, cell count is made into 2 × 106/ mL splenocyte suspensions.Examination
Test and be divided into three groups, first group is that control group is spleen lymph Natural Transformation group;Second group of addition ConA (5 μ g/ml, 100 μ L),
T cell is stimulated to convert;3rd group of addition LPS(10 μg/ml,100 μL), stimulate B cell to convert.Each group cell is sequentially added
In 96 orifice plates, 100 μ L splenocyte suspensions are added per hole, 3 multiple holes are set up per hole.Cell culture condition is:5 %CO2 are cultivated
Case, 37 DEG C, 48 h.Cultivate after 48 h, MTT is added in every hole(5 mg/mL)20 μ L, continue to cultivate after 4 h, centrifugation(2000
Rpm, 10 min), Aspirate supernatant, add 150 μ L DMSO fully dissolve purple crystal, the nm of ELIASA 490 under the conditions of, survey
Fixed each hole OD values.
4.1.4 TNF-α, IL-2 assays
The mice serum dispensed is taken, normal temperature unfreezing is operated in strict accordance with ELISA specifications, clicks and enters 96 orifice plates, and ELIASA is determined
Afterwards, Data Management Analysis is carried out.
4.1.5 the detection of specific IgG antibodies
The mice serum dispensed is taken, normal temperature unfreezing, ELISA method determines mouse specific IgG antibodies level.
4.1.6 fluorescence quantitative RT-RCR is determined
4.1.6.1 RNA is extracted in organizing
Take out in the spleen tissue that each group mouse is stored in liquid nitrogen, the mortar after DEPC water process and be fully ground to powder
Shape.Plus 1 mL Trizol in 1.5 mL centrifuge tubes, add a little spleen powder, after oscillator is fully mixed, stand 5
min.Plus 200 μ L chloroforms in above-mentioned centrifuge tube, cover tightly, after being mixed with hand is reverse, room temperature places 10 min, 12000 g from
The min of the heart 15(In 4 DEG C of centrifuges).4. supernatant is suctioned out in 1.5 new mL centrifuge tubes, plus 500 μ L isopropanols, mix,
It is stored at room temperature after 10 min, 12000 g centrifuge 10 min(In 4 DEG C of centrifuges), retain precipitation.5. plus the cold mL of ethanol 1 of 75 % in
In above-mentioned pelleting centrifugation pipe, fully washing is precipitated, and 7500 g centrifuge 5 min(In 4 DEG C of centrifuges), abandon supernatant.6. drying at room temperature
RNA is to translucent.7. 20 μ L DNase/RNase-Free Deionized Water dissolving precipitations are added into centrifuge tube ,-
80 DEG C freeze.RNA extracts figure, sees accompanying drawing 11.
4.1.6.2 reverse transcription synthesizes cDNA
TNF-α, IL-2 gene order are obtained from database NCBI, and Primer5.0 softwares are used with reference to the gene order of inquiry
The quantitative primer of TNF-α, IL-2 is designed, reverse transcription primer uses the random primer in kit, and fluorescent quantitation primer sequence is shown in Table
11。
The fluorescent quantitation primer sequence of table 11
Kit specification step is spun according to Japan, reverse transcription experiment is carried out, obtains cDNA products, in -80 DEG C of preservations.Reverse transcription
Sample-adding system is shown in Table 12.
The reverse transcription of table 12 is loaded system
Reagent | Sample-adding amount |
Total RNA | 7 μL (1ug) |
primer mix | 0.5 μL |
RT Enzyme Mix | 0.5 μL |
5×RT Buffer | 2 μL |
Total | 10 μL |
4.1.6.3 real time fluorescent quantitative reacts
Using GAPDH as internal control primer, detect TNF-α, IL-2 in mouse spleen tissue using fluorescent dye SYBR-Green I
Middle relative expression quantity, each three repetitions of sample.Amplification reaction condition is as follows:95 DEG C of min of pre-degeneration 5;95 DEG C are reacted 10 seconds,
60 DEG C are reacted 30 seconds, 40 circulations.After reaction terminates, record solubility curve and amplification curve, per the Ct values of hole sample, use 2-△△CTMethod is calculated.Reaction system is shown in Table 13.
The RT-PCR reaction systems of table 13
4.1.7 statistical procedures
Analyzed using SPSS17.0 application software, data with mean+SD (± s) represent.Multigroup is compared and adopts
With one-way analysis of variance method, withP<0.05 represents that difference is statistically significant.
4.2 experimental result
4.2.1 influences of the AF to mouse immune organ organ index
Compared with M groups, N, M-L, M-M group thymus index, index and spleen index have significant difference(P<0.01), M-H groups are without bright
Aobvious change, as shown in table 14.
Influences of the AF of table 14 to mouse immune organ organ index
Note:*P <0.05,** P <0.01,compared with model
4.2.2 influences of the AF to Splenic vein hemodynamics
Compared with M groups, M-L, M-M group Splenic vein hemodynamics rate substantially increase, and pole conspicuousness, such as accompanying drawing 12 is presented in M-L groups
It is shown.
4.2.3 influences of the AF to cytokine TNF-α, IL-2 in mice serum
As shown in Figure 13, compared with M groups, TNF-α content significantly rises in N group serum(P<0.01), in pole conspicuousness, M-
TNF-α content is raised in L, M-M group serum(P<0.05), M-H group TNF-α contents and M group no significant differences.Compared with M groups,
M, M-L group Serum IL-2 are significantly raised(P<0.01), the rise of M-M group IL-2 contents(P<0.05), M-H groups IL-2 contains
There was no significant difference with M groups for amount.
4.2.4 influences of the AF to mouse specific IgG antibodies
As a result show, the immune response that M, M-L, M-M group mouse obtain is good, is compared with M group mouse, antibody level is extremely notable
Property improve(P<0.01), M-H groups are shown in accompanying drawing 14 without significant change.
4.2.5 AF is to TNF-α in mouse spleen tissue, the influence of IL-2 mRNA expression
Fluorescent quantitative PCR result shows that TNF-α, IL-2 melting curves are simple spike, and amplification curve is typical S types, baseline
It is smooth.M-L groups TNF-α, IL-2mRNA expression are respectively 7.73 ± 0.16,10.63 ± 0.34, M-M groups TNF-α, IL-
2mRNA expression is respectively 2.6 ± 0.03,5.43 ± 0.23, is significantly higher than M groups(1.83±0.72、2.45±0.02)(P <
0.01、P <0.05), see accompanying drawing 15.
4.3 discuss
This studies have shown that ICR mouse are administered after 28 d, significantly improve immunosuppressed mice spleen and thymus index;M-L group spleens
Lymphocyte proliferation test is significantly improved compared with M groups;M-L, M-M group mouse specific IgG antibodies are apparently higher than M groups;Immunosupress is small
In mouse serum, tumor necrosis factor TNF-alpha and interleukin 2 IL-2 content are significantly improved.And it is fixed by real-time fluorescence
PCR detections are measured, TNF-α and IL-2 mRNA level in-sites substantially increase.
This experiment is studied with vitro tests such as vivo medicine-feeding research mode combination real-time fluorescence quantitative PCRs, as a result table
Bright, AF can mitigate the atrophy of immune organ phenomenon that CTX is caused.From the point of view of immune response, immunosupress AF low dosages in this experiment
Group, immunosupress AF middle dose groups mouse specific IgG antibodies level are apparently higher than immunosuppression model group mouse, Chen Bo[17],
Guy etc.[18]Research shows that specific IgG antibodies are the main antibody components of serum, can remove harmful complement fragment, suppresses scorching
Disease reaction shields in immunity of organism.The IgG levels of this research show that AF can improve immunosuppressed mice immune response
Ability.Liu Jia etc.[19], Zhao Dingliang etc.[20]Report, IL-2 can promote the increment and differentiation of T, bone-marrow-derived lymphocyte, can induce killing thin
Born of the same parents(LAK)Generation.Immunity of organism function for monitoring can be strengthened.Tan Bing etc.[21], Li Wei etc.[22]Report, TNF-α can be resisted micro-
The function of biotic intrusion and regulation immunity of organism.This time test, with ELISA reagent methods, detect AF immunosupress group mouse blood
IL-2, TNF-α content are significantly improved in clear.Meanwhile, using quantitative fluorescent PCR, detection TNF-α and IL-2 mRNA level in-sites.More than
Result of the test shows that AF has stronger immunopotentiating ability, and the immunosupress of energy antagonism CTX immunologic hypofunction mouse is made
With.But this is tested, and simply the part in immune Research, should further inquire into research, with abundant verification test result.
Brief description of the drawings
Influence of Fig. 1 reaction time to AF synthetic ratios
Influence of Fig. 2 reaction temperatures to AF synthetic ratios
Influence of Fig. 3 solid-liquid ratios to AF synthetic ratios
Influence of Fig. 4 malic acid addition to AF synthetic ratios
Fig. 5 reaction temperatures and the influence of reaction time reciprocation AF synthetic ratio
Fig. 6 reaction temperatures and the influence of solid-liquid ratio reciprocation AF synthetic ratios
Fig. 7 reaction temperatures and the influence of malic acid addition reciprocation AF synthetic ratios
Fig. 8 reaction time and the influence of solid-liquid ratio reciprocation AF synthetic ratios
Fig. 9 reaction time and the influence of malic acid addition reciprocation AF synthetic ratios
The influence of Figure 10 solid-liquid ratios and malic acid addition reciprocation AF synthetic ratios
Figure 11 .RNA extract result figure
Influences of Figure 12 .AF to Splenic vein hemodynamics rate
Influences of Figure 13 AF to TNF-α, IL- alpha contents in mice serum
Influences of Figure 14 .AF to IgG content in mice serum
Figure 15 AF is to TNF-α in mouse spleen tissue, the influence of IL-2 mRNA expression.
Specific embodiment
Embodiment 1
Accurately weigh arginine:Glucose=1g:1g, adds glycerine 10ml and citric acid 0.1g, and shaking table 160rpm is mixed,
120min is reacted under the conditions of 85 DEG C, column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 55.52%.
Embodiment 2
Accurately weigh arginine:Fructose=1g:1g, adds glycerine 10ml and citric acid 0.1g, and shaking table 160rpm is mixed, and 85
120min is reacted under the conditions of DEG C, column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 58.52%.
Embodiment 3
Accurately weigh arginine:Fructose:Xylose=1g:0.5g:0.5g, adds glycerine 10ml and citric acid 0.1, shaking table
160rpm is mixed, and 180min is reacted under the conditions of 85 DEG C, and column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 60.52%.
Embodiment 4
Accurately weigh arginine:Xylose=1g:1g, adds glycerine 10ml and citric acid 0.1g, and shaking table 160rpm is mixed, and 85
120min is reacted under the conditions of DEG C, column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 65.52%.
Embodiment 5
Accurately weigh arginine:Xylose=1g:1g, adds propane diols 10ml and vitamin C 0.1g, and shaking table 160rpm is mixed,
120min is reacted under the conditions of 85 DEG C, column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 45.52%.
Embodiment 6
Accurately weigh arginine:Xylose=1g:1g, adds isopropanol 10ml and vitamin C 0.1g, sodium sulfite 0.05g shaking tables
160rpm is mixed, and 120min is reacted under the conditions of 85 DEG C, and column front derivation efficient liquid phase detects AF contents, and synthetic ratio is 45.52%.
Embodiment 7
Accurately weigh L-arginine:D-Arg:Xylose=0.5g:0.5g:1g, adds isopropanol 10ml and vitamin C
0.1g, sodium sulfite 0.05g shaking tables 160rpm are mixed, and 120min, column front derivation efficient liquid phase detection AF are reacted under the conditions of 85 DEG C
Content, synthetic ratio is 65.52%.
Embodiment 8
Anti-senility oral liquid
The AF powder of Example 1 after purification, is fitted into vial after being configured to the 35mg/ml aqueous solution, sterilizing, is made every
Branch 10ml oral liquid.Other requirements meet《Pharmacopoeia of People's Republic of China》2010 editions relevant regulations about oral liquid.
Embodiment 9
Beauty and skin care water
The AF powder purified in Example 1, is added in surfactant matrix liquid, and AF ultimately joins concentration for 100mg/100mL.Its
He requires to meet China cosmetic production requirement specification.
Bibliography
[1] Takaku, T., Han, L.K., Kameda K., et al. Production of arginyl-
frictosyl glucose during processing of red ginseng. J. Tradit. Med. 1996, 13,
118-123.
[2] Suzuki ,Y., Choi, K.J., Uchida,K., et al. Arginyl-fructosyl-glucose
and arginyl-fructose, compoundsrelated to browning reaction in the model
system of steaming and heat-drying processes for the preparation of red
ginseng. J. Ginseng Res. 2004, 28, 143-148.
[3] the artificial synthesized L-arginine monoglycosides of Zhao Ting(AF)And its anti-diabetic pharmacology activity research [D] Changchun:Jilin
Agriculture university, 2013.
[4] Kwang-Hyoung Lee, Kyoung-Soo Ha, Sung-Hoon Jo, et al. Effect of Long-
Term Dietary Arginyl-Fru-ctose (AF) on Hyperglycemia and HbA1c in Diabetic
db/db Mice. J. Mol. Sci. 2014, 15, 8352-8359.
[5] Cho, E.J.;Piao, X.L.; Jang, M.H. et al. The effect of steaming on the
free amino acid contents and antioxidant activity of Panax ginseng. J. Food
Chem. 2008,107: 876–882.
[6] By Lee, Jung-Sook; Kim, Gyo-Nam; Lee, Sang-Hyun, et al. In vitro and
cellular antioxidant activity of arginyl-fructose and arginyl-fructosyl-
glucose. J. Food Science and Biotechnology 2009, 18(6), 1505-1510.
[7] Keum,Y.S; Park,K.K; Lee,J.M., et al. Antioxidant and anti-tumor
promoting activities of the methanol extract of heat-processed ginseng. J.
Cancer Lett. 2000, 150,41-48.
[8] the practical medicine of Cheng Lichun, progress [J] of model green grass or young crops active targeting liposomes in antineoplaston and clinic,
2011,14 (5):426-429.
[9] Dan Zhang, Yuhong Sun, Mao Li, Qin Sun, Minghua Liu. Effects ofPeriplaneta americana polypeptideextracts on tumor growth and immune function
in tumor-bearing mice [J].Chinese Journal of New Drugs ,2015,24(6):681-686.
[10] Xinrui Yang, Gang Wang, Libin Ji, Haiyan Wang. Effects of Arenaria
Kansuensis Aqueous Extract on Immune Function of H22 Tumor-bearing Mice[J]
.Cancer Res Prev Treat ,2015, 42(7):662-665.
[11] Xiong Q, Jiao Y, Zhao X, et al. Purification, characterization and
immunostimul-atory activity of polysaccharide from Cipangopaludina chinensis
[J] Carbohydrate Polymers, 2013,98 (1): 217- 223.
[12] Tang Yan, Zhang Dan, Meng Xianglin, wait influence of the TGPs liposome to tumor-bearing mice tumour growth and immunologic function
[J] Chinese Journal of New Drugs, 2014,23(21):2547-2551.
[13] Li Molin, Li Zhuangang, the grand melphalans of Shu Xiao cure the process of tumor-bearing mice and relation [J] the cells of TNF-α with
Molecular immunology magazine, 2007,23 (4):320.
[14] Jakhar R, Paul S, Pard YR, el al.3,5,7,3’,4’-Pentamethoxyflavone, a
quercetin derivative protects DNA from oxidative challenges: potential
mechanism of action[J].Photochem Photobiol B, 2014, 131: 96-103.
[15] Fuhua Li, Dong Liu, Jian Ming. Cellular Antioxidant and
Antiproliferative Activities of Flavonoids Extracted from Tartary Buckwheat
(Fagopyrum tartaricum (L.) Gaertn) Bran [J].Food Science,2014.35(7):58-63.
[16] Esterbauer H, Schaur R J, Zolner H. Chemistry and biochemistry of 4-
hydroxynonenal, malonaldehyde and related aldehydes [J]. Free Radic Biol Med,
1991, 11(1): 81-128.
[17] Chen Bo .H-IgG are damaged to Neonatal Rat Brain ischemic hypoxia protective effect and Mechanism Study [D] Changchun:It is lucky
Woods university, 2013,16-22.
[18] Guy B, Hessler C, Fourage S, et al.Systemic immunization with urease
protects mice against
Helicobacter pylori infection J. Vaccine,1998,16(8):850-856.
[19] Liu Jia, Dan Anshan, grandson enter the progress of magnificent interleukin 2s with applying [J] HEILONGJIANG ANIMAL SCIENCE AND VETERINARY MEDICINEs,
2009(21):57-61.
[20] Zhao Dingliang, single flat cytokine -2s latest Progress [J] JOURNAL OF MICROBIOLOGYs of wind, 2013,5(4):77-
79.
[21] Tan Bing, Li Yuyuan, the international clinical practice magazines of progress [J] of Nie Yuqiang tumor necrosis factor-alphas, 2007,5
(3):129-133.
[22] progress [J] the animal medicines progress of Li Wei, Liu Jia, Bai Jiayuan cachectins, 2010,6(12):
12-14。
Claims (10)
1. under certain temperature, time, solvent, utilize synthesis of glycoside under the conditions of amino acid and monose, it is characterised in that amino
The ratio of acid and monose is 1:0.5-2, synthetic ratio is more than 63%.
2. the glucosides synthesized according to claim 1, it is characterised in that the amino acid required in building-up process can be L-
The mixture of arginine, D-Arg one or two kinds of therein.
3. the glucosides synthesized according to claim 1, it is characterised in that the monose required in building-up process can be D- Portugals
One or more kinds of mixtures in grape sugar, D-Fructose, D- galactolipins, D- xyloses.
4. the glucosides synthesized according to claim 1, it is characterised in that the generated time required in building-up process is 120-
300min。
5. the glucosides synthesized according to claim 1, it is characterised in that required optimum synthesising temperature is in building-up process
80℃。
6. the glucosides synthesized according to claim 1, it is characterised in that the solvent required in building-up process is propane diols, third
One or more kinds of mixed solvents in triol, propyl alcohol, isopropanol.
7. the glucosides synthesized according to claim 1, it is characterised in that the sodium sulfite that can also be added in building-up process, dimension
One or more kinds of mixtures in raw element C, vitamin E.
8. the glucosides synthesized according to claim 1, it is characterised in that citric acid, malic acid can also be added in building-up process
Etc. one or more kinds of mixtures in edible organic solid acid.
9. the glucosides synthesized according to claim 1, it is characterised in that with removing hydroxyl radical free radical and superoxide anion certainly
By base, improve the immunity of immunosuppressed mice, suppress H22The purposes of tumor-bearing mice tumour growth.
10. the glucosides synthesized according to claim 1, it is characterised in that can be used for adjuvant therapy of tumors, carry and exempting from
In the medicine of epidemic disease power, food, health products.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610172045.6A CN107011393A (en) | 2016-03-24 | 2016-03-24 | A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610172045.6A CN107011393A (en) | 2016-03-24 | 2016-03-24 | A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107011393A true CN107011393A (en) | 2017-08-04 |
Family
ID=59439404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610172045.6A Pending CN107011393A (en) | 2016-03-24 | 2016-03-24 | A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107011393A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518146A (en) * | 2020-06-10 | 2020-08-11 | 吉林农业大学 | Novel large-scale synthesis and preparation method of compound arginine fructoside-AF |
CN111592575A (en) * | 2020-06-10 | 2020-08-28 | 吉林农业大学 | Novel synthesis method of compound arginine diglycoside AFG |
CN115073538A (en) * | 2022-07-20 | 2022-09-20 | 吉林农业大学 | Novel method for synthesizing compound arginine fructoside AF in ginseng |
CN116082421A (en) * | 2022-10-09 | 2023-05-09 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178687A (en) * | 2011-03-21 | 2011-09-14 | 郑毅男 | Preparation method of arginine glucoside and application in medicament for treating diabetes |
CN104447892A (en) * | 2014-09-11 | 2015-03-25 | 郑毅男 | Arginine-fructosyl-glucose detection method and medical application thereof |
CN104610384A (en) * | 2014-11-11 | 2015-05-13 | 郑毅男 | Synthetic method for argininyl-fructosy-glucose and application of argininyl-fructosy-glucose in anti-aging |
CN105085584A (en) * | 2014-06-28 | 2015-11-25 | 郑毅男 | Preparation method and medical use of argininyl fructose (AF) |
-
2016
- 2016-03-24 CN CN201610172045.6A patent/CN107011393A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102178687A (en) * | 2011-03-21 | 2011-09-14 | 郑毅男 | Preparation method of arginine glucoside and application in medicament for treating diabetes |
CN105085584A (en) * | 2014-06-28 | 2015-11-25 | 郑毅男 | Preparation method and medical use of argininyl fructose (AF) |
CN104447892A (en) * | 2014-09-11 | 2015-03-25 | 郑毅男 | Arginine-fructosyl-glucose detection method and medical application thereof |
CN104610384A (en) * | 2014-11-11 | 2015-05-13 | 郑毅男 | Synthetic method for argininyl-fructosy-glucose and application of argininyl-fructosy-glucose in anti-aging |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518146A (en) * | 2020-06-10 | 2020-08-11 | 吉林农业大学 | Novel large-scale synthesis and preparation method of compound arginine fructoside-AF |
CN111592575A (en) * | 2020-06-10 | 2020-08-28 | 吉林农业大学 | Novel synthesis method of compound arginine diglycoside AFG |
CN115073538A (en) * | 2022-07-20 | 2022-09-20 | 吉林农业大学 | Novel method for synthesizing compound arginine fructoside AF in ginseng |
CN116082421A (en) * | 2022-10-09 | 2023-05-09 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
CN116082421B (en) * | 2022-10-09 | 2023-07-07 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103800390B (en) | Health-care product with immunity-reinforcing and liver-protecting functions, preparation method and application thereof | |
CN107011393A (en) | A kind of arginine monoglycosides(AF)Novel synthesis and its purposes in terms of medicine | |
CN103880910B (en) | A kind of preparation method and its usage of Cyclosiversigenin | |
EP1092765A2 (en) | Germination-activated red Ganoderma lucidum spores and method for producing the same | |
AU2020100921A4 (en) | Preparation And Quality Control Method Of Periplaneta Americana Linn. Anti-Tumor Capsule | |
CN1857394A (en) | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method | |
CN109400742A (en) | A kind of dendrobium devonianum refined polysaccharide and its preparation method and application | |
CN101596246B (en) | Smoked plum extractive and wild jujube seed extractive compound preparation as well as preparation method and application thereof | |
CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
CN105769926A (en) | Skin mucus extracts of andrias davidianus Blanchard for preparing anti-breast cancer drugs and application thereof | |
CN101580805A (en) | Brefeldin A-producing bacteria and method for preparing brefeldin A by fermentation | |
CN104224863B (en) | Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug | |
US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
CN1202135C (en) | Chi lucid ganoderma polysaccharide and prep. and use thereof | |
CN101167755B (en) | Method for preparing centipede polysaccharide protein composition with anti-tumor activity and use | |
CN107383150B (en) | A kind of compound and its preparation method and application with antihepatitis activity | |
CN105560352A (en) | Duck viral hepatitis resisting astraglus polysaccharide phosphorylated molecular modification method | |
CN106924297A (en) | A kind of Lachnum intracellular melanin as acute liver damage medicine purposes | |
CN104147038A (en) | Fungal polysaccharide and composition thereof with anti-gastric ulcer effects | |
CN107028989A (en) | Application of the miracle fruit leaf extract in molecular targeted agents are prepared | |
CN102614247A (en) | Application of red bean (bean, winged bean) extracts in preparing anti-diabetes medicines | |
CN102119953A (en) | Application of euphorbia humifusa wild extract | |
CN101683320A (en) | Olprinone hydrochloric parenteral solution and method for preparing same | |
CN101711790A (en) | Wild Juglans mandshurica bark water extract used for curing liver cancer | |
CN106177035B (en) | Preparation method and application of effective rosa chinensis flower extract with blood sugar reducing and anticancer functions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170804 |
|
WD01 | Invention patent application deemed withdrawn after publication |